MIF and colorectal carcinoma: Furthermore, it was discovered that KRAS mutant CRC cells treated with refametinib, a MEK inhibitor, stimulated MIF production and resulted in the activation of STAT3 (signal transducer and activator of transcription 3) and MAPK, which promotes resistance to this medication (167).